

CURRICULUM VITAE

Marine Meliksetyan

Address:

European Institute of Oncology
Department of Experimental Oncology
Via Adamello 16, 20139, Milan, Italy

Phone:

+39 3465761104

E-mail:

marine.melixetian@gmail.com

Citizenship:

Italian

Skills&Competences:

Molecular Cellular Biology, Genomics, Bioinformatics, Cancer Research, Science writing and translation

Computer Skills:

MS office, Adobe Photoshop, Adobe Illustrator, ImageJ, Linux Systems, Scripting in Bash, Awk and R. NextGen Sequencing Data analysis

Science Writing:

Long term experience in research article, review, grant wrting, editing manuscripts, graduate and PhD thesis manuscripts, peer review for research journals in field of Molecular Oncology, Clinical Research, Cell Biology, Genetics and Genomics

Excellent knowledge of biological, medical , pharmaceutical concepts and terminology. Ability to work collaboratively, meet deadlines, have attention to details, perform multiple tasks simultaneously and prioritize.

Language and Translation Skills:

Russian, Armenian -Native. English, Italian -full professional proficiency.

More than 10 years experience as freelance translator English- to-Russian, Italian-to-Russian, English-to-Armenian, Armenian-to-English, Italian-to-Armenian of texts and articles in field of medicine, science, history, politics and sociology.

CAT tools usage.

Professional Background:

2010-date

Research Scientist, European Institute of Oncology, Milan, Italy

Genome wide analysis of DNA methylation, m6A-RNA methylation and gene expression in melanomas. Studies on function, in vitro and in vivo targeting lncRNAs in melanoma

The role of lncRNAs in nonsense mediated decay (NMD) pathways and immunotherapy response in melanoma. Bioinformatic analysis of prognostic gene signatures in cancer.

Postdoctoral fellow, European Institute of Oncology, Milan, Italy.

Collaboration with Dr Kristian Helin and Claus Storgaard Soprensen (Biotech Research and Innovation Centre (BRIC), Copenhagen, DK).

2005-2009

Genome wide shRNA screen to identify novel regulators of DNA damage induced G2/M. We identified NEK11 kinase as a critical regulator of DNA damage G2/M checkpoint.

1999-2004

Postdoctoral fellow European Institute of Oncology, Milan, Italy.

Identification of novel regulators of DNA replication in mammalian cells. I have identified that crucial role of CDT1- Geminin interactions DNA origin licensing. We have demonstrated that loss of geminin is sufficient to promote re-replication of DNA .

Study on the role of MAD2 and MAD1 proteins in spindle checkpoint function.

1995-1999

Staff Scientist at the Institute of Cytology, Russian Academy of Sciences, St- Petersburg, Russia

Coordinator of a project on drug resistance mechanisms in hematopoietic cancer cell lines

1992-1995

PhD Student at Institute of Cytology, Russian Academy of Sciences, St- Petersburg . PhD thesis

dedicated to mechanisms of drug resistance in cancer cell lines

1989-1991

Graduate student and research fellow, Laboratory of Neuropharmacology, Institute of Pharmacology, Moscow, Russia. In my graduate thesis work I identified novel type of receptor for benzodiazepine-receptor antagonists beta- carbolines.

Education

1996

PhD in Molecular and Cellular Biology from Institute of Cytology ,Russian Academy of Sciences,St-Petersburg (Russia)

1989

MSc in Biophysics from Yerevan State University (USSR)

Review and teaching activities:

Ad hoc reviewer for EMBO J., FASEB J.,Oncogene, Oncotarget and others.

Grant review and scientific writing for Italian Association for Cancer Research (AIRC), National Natural

Science Foundation (China) and others.

PhD student supervision and teaching at European School of Molecular Medicine (SEMM), Milan , Italy

PUBLICATIONS

1. Melixetian, M., Pelicci , Luisa Lanfrancone, L (2022).

Regulation of lncRNAs in melanoma and their functional roles in the metastatic process.

Cells (In press)

2. **Melixetian, M.**, Bossi,D., Mihailovich,M., Punzi,S., Barozzi,I., Marocchi, F., Cuomo, A., Bonaldi, T., Testa, G.,Marine,J.C., Leucci, E., Minucci, S., Pelicci, PG and Lanfrancone L. (2021)

TINCR lncRNA suppresses metastatic dissemination in melanoma by preventing ATF4 translation.

EMBO Reports 22: e50852.

3. Punzi S, **Meliksetian** M, Riva L, Marocchi F, Pruneri G, Criscitiello C, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, Curigliano G, Pelicci PG, Lanfrancone L. (2019) Development of

- Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. *Cells* 6:605.
3. Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, Criscitiello C, Lovati G, **Meliksetyan M**, Carugo A, Curigliano G, Natoli G, Pelicci PG, Lanfrancone L. (2019) WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast Cancer Res* 21:123-141.
 4. Storgaard Sørensen ,C, **Melixetian,M**, Kjærsgaard Klein, D, and Helin K.(2010) NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling *Cell Cycle* 210: 450- 455
 5. **Melixetian M**, Klein, D., Sørensen CS., and Helin K(2009). NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint *Nature Cell Biology*,10 :1247-1253
 6. Ballabeni A, Zamponi R, Caprara G, **Melixetian M**, Bossi S, Masiero L, Helin K.(2009) Human CDT1 associates with CDC7 and recruits CDC45 to chromatin during S phase. *J Biol Chem.* **284**:3028-3036.
 7. Caprara G., Zamponi R., **Melixetian, M.**, Helin K. (2009) Isolation and characterization of DUSP11, a novel p53 target gene J. *Cell. Mol. Med* .13: 2158-2170
 8. **Melixetian M.**, Helin K (2004).Geminin: a major DNA replication safeguard in higher eukaryotes. *Cell Cycle* 8: 1002-1004.
 9. **Melixetian M**, Ballabeni A, Zamponi R, Masiero L, Marinoni F, Helin K. (2004) Human Geminin promotes pre-RC formation and DNA replication by stabilizing CDT1 in mitosis.*EMBO J* . 23: 3122-3132.
 - 10.**Melixetian M**, Ballabeni A, Masiero L, Gasparini P, Zamponi R, Bartek J, Lukas J, Helin K.(2004) Loss of Geminin induces rereplication in the presence of functional p53. *J Cell Biol.* 165: 473-82.
 11. **Melixetian MB**, Pavlenko MA., Beriozkina EV., Kovalyova ZV., Sorokina E., Ignatova (2003) TN., Grinchuk TM Mouse Myeloma Cell Line Sp2/0 Multidrug resistant variant as a parental cell line Hybridoma Constructon . *Hybridoma and Hybridomics* 22: 321-327.
 12. **Melixetian M**, Sironi L Faretta M, Prosperini E, Helin K, Musacchio A. (2001) Mad2 binding to Mad1 and Cdc20, rather than oligomerization, is required for the spindle checkpoint. *EMBO J* 20: 6371-6382 .
 13. Petersen BO, Wagener C, Marinoni F., Kramer E., **Melixetian M.**, Denchi EL, Gieffers C, Matteucci, C, Peters J-M., Helin K. (2000) Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1. *Genes & Dev.* 14 : 2330-2343.
 14. **Melixetian MB**, Beryozkina EV, Pavlenko MA, Grinchuk TM (2000) Altered expression of DNA-topoisomerase IIalpha is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells. *Leukaemia Res.* 24 : 831-837.
 15. **Meliksetian, M.B.**, Davtyan, T.K., Chirkowa, I.V., Alexanyan, Yu.T., Ignatova. ,T.N (1997.) Alterations in immunoglobulin synthesis during adriamycin induced apoptosis in mouse hybridoma cells *Cell Biology International* 21 :69-74